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Abstract 
Background: Hypoxia inducible factor-1 (HIF-1) is considered as the most activated transcriptional factor in response 
to low oxygen level or hypoxia. HIF-1 binds the hypoxia response element (HRE) sequence in the promoter of differ-
ent genes, mainly through the bHLH domain and activates the transcription of genes, especially those involved in 
angiogenesis and EMT. Considering the critical role of bHLH in binding HIF-1 to the HRE sequence, we hypothesized 
that bHLH could be a promising candidate to be targeted in hypoxia condition.
Methods: We inserted an inhibitory bHLH (ibHLH) domain in a pIRES2-EGFP vector and transfected HEK293T cells 
with either the control vector or the designed construct. The ibHLH domain consisted of bHLH domains of both HIF-
1a and Arnt, capable of competing with HIF-1 in binding to HRE sequences. The transfected cells were then treated 
with 200 µM of cobalt chloride  (CoCl2) for 48 h to induce hypoxia. Real-time PCR and western blot were performed to 
evaluate the effect of ibHLH on the genes and proteins involved in angiogenesis and EMT.
Results: Hypoxia was successfully induced in the HEK293T cell line as the gene expression of VEGF, vimentin, and 
β-catenin were significantly increased after treatment of untransfected HEK293T cells with 200 µM  CoCl2. The gene 
expression of VEGF, vimentin, and β-catenin and protein level of β-catenin were significantly decreased in the cells 
transfected with either control or ibHLH vectors in hypoxia. However, ibHLH failed to be effective on these genes and 
the protein level of β-catenin, when compared to the control vector. We also observed that overexpression of ibHLH 
had more inhibitory effect on gene and protein expression of N-cadherin compared to the control vector. However, it 
was not statistically significant.
Conclusion: bHLH has been reported to be an important domain involved in the DNA binding activity of HIF. How-
ever, we found that targeting this domain is not sufficient to inhibit the endogenous HIF-1 transcriptional activity. 
Further studies about the function of critical domains of HIF-1 are necessary for developing a specific HIF-1 inhibitor.
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Background
In the past two decades, gene-therapy has received great 
attention in the fields of medical sciences. Although it 
could be more favorable for the treatment of highly prev-
alent diseases such as cancer, the most effective results 
have been reported from monogenic diseases, as they are 
caused by a mutation in a single gene [1]. Cancer is one 
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of the most complicated diseases for achieving a success-
ful gene therapy. So that, in spite of several ongoing clini-
cal trials in different countries, only a few of them show 
promising benefits, indicating that cancer gene therapy 
requires further modifications to be applied in rou-
tine clinical practice [1, 2]. To achieve a successful gene 
therapy, first of all, we should have a clear picture of the 
genetic basis of the studied disease. Furthermore, identi-
fication of the most prominent key proteins and under-
standing the functions and interactions of the involved 
protein domains is necessary. Finally, the overlapping of 
different signaling pathways should be clearly considered 
[1, 3].
Hypoxia is commonly observed in the local micro-
environment of solid tumors and plays a critical role 
in cancer progression [4, 5], metastasis [6], therapeu-
tic resistance [7–9], and poor prognosis [6], making it an 
attractive target for cancer therapy. In contrast to normal 
cells, cancer cells activate several pathways at decreased 
oxygen tensions to survive and to continue their devel-
opment. Hypoxia inducible factor-1 (HIF-1) is the most 
prominent transcriptional factor induced by cancer cells 
in possibility leading to an aggressive phenotype follow-
ing hypoxic conditions [10, 11]. HIF-1 has a heterodi-
meric structure and consists of two basic helix-loop-helix 
(bHLH) proteins, including HIF-1a and aryl hydrocarbon 
receptor nuclear translocator (Arnt). In contrast to Arnt, 
which has constitutive expression, HIF-1a has a short 
half-life and degrades following hydroxylation and ubiq-
uitination [12, 13]. Hypoxia, oncogenes, and chemical 
reagents such as cobalt may stabilize HIF-1a and cause 
accumulation of this protein in the cells [14]. In these 
conditions, HIF-1a migrates into the nucleus, dimer-
izes with Arnt, and binds the hypoxia element response 
(HRE) sequence in the promoter of related genes like vas-
cular endothelial growth factor (VEGF), N-cadherin, and 
vimentin [15, 16]. In addition to HIF-1a, Arnt also dimers 
with dioxin receptor (DR) [17] and binds to the xenobi-
otic response element (XRE) in the  promoter of target 
genes such as cytochrome P4501A1 (CYP1A1) in order 
to promote the transcription of xenobiotic-metabolizing 
enzymes [18].
Considering the critical role of HIF in different steps 
of cancer progression, several attempts have been done 
to target this pathway. Based on personalized medicine, 
a specific HIF-1 inhibitor could be applied for patients 
with high HIF activity. This type of patient stratification 
may also help to avoid unnecessary therapies and result 
in a  more favorable prognosis [10]. However, HIF is a 
complex pathway, overlapping mechanisms and signal-
ing cascades, therefore, developing a HIF specific inhibi-
tor is a major challenging task. Although some agents can 
indirectly affect the HIF-1 pathway [10]; up to now, no 
specific HIF-1 inhibitor has been clinically approved. For 
example, echinomycin, a natural cyclic peptide belonging 
to the  quinoxaline antibiotic family, has  been suggested 
as a small inhibitor that interferes with the HIF-1–DNA 
interaction [19]. However, echinomycin is not the HIF 
specific inhibitor and affects other transcription factors 
that have similar core-binding sites in their DNA con-
sensus sequences [19].  Moreover, confirmation of its 
cytotoxicity in several clinical trial phases has limited 
its clinical application [10]. Nonspecific inhibitors are 
usually associated with adverse side effects and limited 
therapeutic efficacy. It is thus necessary to develop novel 
and more specific inhibitory molecules, capable to hinder 
HIF-1 pathway while escaping other pathways. Decipher-
ing the molecular structure of HIF-1a domains and their 
critical functions in this pathway will help to design novel 
strategies for further improving the efficacy of current 
drugs and possibly identification of novel inhibitors [10].
Previous studies have reported that bHLH domains 
have a critical role in binding HIF-1a-Arnt to the HRE 
sequence or DR-Arnt to XRE sequence. X-ray crystallo-
graphic and nuclear magnetic resonance (NMR) studies 
have demonstrated that bHLH domain contains argi-
nine and lysine residues, capable of binding the core 
nucleotides of HRE sequences [20, 21]. This domain 
inserts alpha helices into the major groove face of the 
HRE sequences in a pseudo-symmetric fashion, mainly 
through hydrogen bonds and van der Waals interactions 
[22].
In this regard, targeting DNA binding activity through 
the  bHLH domain was considered as the main goal 
of some studies. Kong et  al. indicated that the HIF-1a 
bHLH-PAS and Arnt bHLH-PAS truncated proteins, 
mediated the DNA-binding activity of HIF-1 [19]. In 
another study, Pongratz et  al. reported that the bHLH 
regions of DR and Arnt molecules are sufficient for XRE 
recognition [23], suggesting that targeting only bHLH 
domain might be a promising approach. However, few 
studies proposed that the per-Arnt-Sim  (PAS) domain 
also contributes to  the DNA-binding activity of HIF-1 
[22, 24]. PAS is mainly responsible for the dimerization of 
HIF-1a-Arnt and DR-Arnt. However, when PAS domain 
is deleted or any distinct point mutations are applied 
within this region, bHLH takes the PAS role in dimeri-
zation. In this case, the DNA-binding activity of this 
domain is reduced, while no significant disruption occurs 
in dimerization [24, 25].
According to the previously mentioned findings, we 
assumed that a truncated protein, containing the bHLH 
domains of HIF-1a dimerized with bHLH of Arnt, could 
reverse the DNA binding activity of HIF in the absence 
of the PAS domain and compete with the cell HIF-1 mol-
ecule in binding to the HRE sequence of downstream 
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genes. Therefore, we designed a small inhibitory bHLH 
domain (ibHLH) protein, composed of both regions of 
HIF-1a bHLH and Arnt bHLH domains, to figure out 
whether it is capable to bind the HRE sequence and 




HEK293T cells were purchased from the Stem Cell 
Technology Research Center of Iran and propagated 
using complete medium composed of high glucose Dul-
becco’s modified eagle medium (DMEM), supplemented 
with 10% fetal bovine serum (FBS) and penicillin–
streptomycin and maintained at 37  °C  in a  humidified 
atmosphere containing 5% CO2.
MTT cell proliferation assay
MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetra-
zolium bromide) cell proliferation assay was performed 
to assess the toxic effect of Cobalt (II) chloride  (CoCl2) 
(Thermo Fisher Scientific, Miami, Florida, USA) as it 
is an hypoxia-mimicking substance, on the viability of 
HEK293T cells. Briefly, 2.5 × 103 cells were cultured in 
complete medium in 96-well plates and during the fol-
lowing day were treated with 150 or 200  µM  CoCl2 for 
24–48 h. At the end of the incubation time, the media of 
each well was removed and replaced with fresh serum 
free medium, supplemented with 20 µl of MTT solution 
(5 mg/ml; Sigma, St. Louis, Missouri, USA). After 3 h, the 
MTT solution was removed and 100 µl dimethyl sulfox-
ide (DMSO) was added to each well and the plate was 
maintained at 37  °C on an orbital shaker. After 15  min, 
the absorbance was recorded at 570  nm using a micro-
plate reader.
Hypoxia induction
To induce hypoxia, 1.5 × 105 HEK293T cells were treated 
with 150 or 200 µM concentrations of  CoCl2 for 24–48 h. 
The efficiency of the hypoxia was evaluated by real-time 
PCR to determine VEGF gene expression and also by 
western blot analysis of HIF-1a at the protein level.
Real‑time PCR
Total RNA was extracted using  TRIzol® reagent (Gene-
All, Seoul, South Korea) and qualified with NanoDrop 
2000c spectrophotometer (A260/A280 ratio was 1.8–2.0 
and A260/A230 ratio was > 1.8). cDNA was synthesized 
from 1  μg/μl of RNA according to the manufacturer’s 
instructions (Thermo Fisher Scientific, Miami, Florida, 
USA). The real-time PCR was performed in 20  μl reac-
tion volumes, containing 10  μl of 2X SYBR-Green mix 
(Biofact, Daejeon, South Korea), 1 μl cDNA and 0.5–1 μl 
of both reverse and forward primers. Two-step thermal 
cycling consisted of 1 cycle of 95 °C for 5 min, followed 
by 40 cycles of 95 °C for 15 s and 56–60 °C, for 40 s. The 
details of the primers sequence and their annealing tem-
perature are presented in Table 1. HPRT1 was considered 
as the housekeeping gene and  2−(∆∆CT) value was calcu-
lated to get the relative expression.
Western blotting analysis
HEK293T cells were washed with phosphate buffered 
saline (PBS) and lysed with radio immunoprecipita-
tion assay (RIPA; Santa Cruz Biotechnology, Dallas, 
Texas, USA) buffer, containing protease inhibitor cock-
tail. Equal concentrations of whole cell lysate (approxi-
mately 60  µg), were loaded on 12.5% SDS-PAGE slabs 
after measurement of the protein content of the extracts 
with bicinchoninic acid (BCA) kit. The resolved proteins 
were transferred to the polyvinylidene difluoride (PVDF) 
membrane and the membrane was blocked with 5% skim 
milk in PBS containing 0.2% tween, overnight (4 °C). The 
membrane was incubated with mouse anti human HIF-1a 
(1:100, Santa Cruz Biotechnology, Dallas, Texas,), rabbit 
anti human N-cadherin (1/500, Abcam, Cambridge, UK), 
β-catenin (1/3000, Abcam, Cambridge, UK) and β–actin 
(1:1000, Abcam, Cambridge, UK) diluted in 2% skim 
milk/PBST at 4  °C overnight, followed by 3 washes in 
PBST (3 times × 5 min). Then, the membrane was incu-
bated with appropriate dilutions of secondary antibodies 
at RT for 1 h, followed by 4 washes with PBST and final 
visualization using enhanced chemiluminescence reagent 
(Intron Biotechnology, Seongnam-Si, South Korea).
Plasmid constructs
The ibHLH (HIF-1a bHLH domain: amino acids # 17–70, 
Arnt bHLH domain: amino acids # 89–142) was cloned 
Table 1 The details of primers sequence and the annealing 
temperature
Primer Sequence (forward, reverse) Annealing 
temperature
HPRT1 F: AAT TAC TTT TAT GTC CCC TGT TGA CTGG 
R: GCT ATA AAT TCT TTG CTG ACC TGC TG
63
VEGF F: TTG CCT TGC TGC TCT ACC TCCA 
R: GAT GGC AGT AGC TGC GCT GATA 
62.5
HIF-1a F: TGA GTT CGC ATC TTG ATA AGGC 
R: ACA AAA CCA TCC AAG GCT TTCA 
63
N-cadherin F: GGA CAG TTC CTG AGG GAT CA
R: GGA TTG CCT TCC ATG TCT GT
62.5
Vimentin F: GGT GGA CCA GCT AAC CAA CGA 
R: TCA AGG TCA AGA CGT GCC AGA 
62.5
β-catenin F: AAA ATG GCA GTG CGT TTA G
R: TTT GAA GGC AGT CTG TCG TA
62
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into the multiple cloning site (MCS) of pIRES2-EGFP 
plasmid (Fig. 1) with a linker between them and verified 
by sequencing (Additional file  1). Moreover, to increase 
the specificity of ibHLH in hypoxia, and avoid the 
unwanted overexpression in normal condition, we fused 
the oxygen depended domain (ODD) domain to C-ter-
minal of ibHLH (Fig. 1). ODD domain is responsible for 
stabilizing HIF-1 in hypoxia and causes HIF-1 degrada-
tion in normoxic conditions through ubiquitination and 
proteasomal degradation.
Transient transfection
HEK293T cells were transiently transfected with either 
control pIRES2-EGFP or ibHLH- pIRES2-EGFP plas-
mids using polyethylenimine (PEI; Sigma, St. Louis, Mis-
souri, USA) reagent. Briefly, 1.3 × 105 cells were seeded 
in 2 ml 10% FBS medium in 6-well plates overnight. On 
the day of transfection, the medium was replaced with 
1.5 ml of antibiotic-free medium, containing 1% FBS and 
incubated for 2  h. The transfection complex was pre-
pared by adding 500 µl of serum-free and antibiotic-free 
medium, 5 µg/µL DNA (Control or ibHLH vectors), and 
12.5 µl PEI with the respective order and incubated at RT 
for 10  min. The transfection complex was added drop-
wise to the cells. After 4 h, the medium was aspirated and 
replaced with complete medium. Transfection efficiency 
was controlled with invert fluorescent microscopy and 
flow cytometry methods and the side-effects of transfec-
tion on the viability of the cells were evaluated by pro-
pidium iodide staining. After 24 h of the transfection, the 
cells were treated with 200 µM  CoCl2 for 48 h (as optimal 
concentration and time for hypoxia induction) and then 
were collected for molecular analysis.
Statistical analysis
Statistical parameters and tests are reported in the leg-
ends of figures. All gene level data were presented as 
mean (± SD). One-way ANOVA, Bonferroni analysis was 
performed for all the datasets that required comparison 
among more than two  independent groups. At the pro-
tein level, we performed nonparametric tests. The data 
were presented as the median (± IQR) and Kruskal–Wal-
lis, Dunn test was performed to compare between two 
or more independent groups. Moreover, Benjamini–
Hochberg–was done to control the False Discovery Rate 
(FDR) in multiple testing experiments. All of the data is 
presented by GraphPad Prism 7 (GraphPad Prism Soft-
ware, San Diego, CA, USA) and the statistical analysis 
was performed using STATA/SE  version 12.0 software 
(STATA Corp., TX, USA).
Results
Toxicity of  CoCl2 on the HEK293T cells
The MTT assay demonstrated that both of the studied 
concentrations of  CoCl2 (150  µM and 200  µM) had no 
significant side-effect on the viability of HEK293T cells 
after 24 and 48 h compared to the control group (p > 0.05) 
(Fig. 2).
Fig. 1 Restriction map of pIRES2-EGFP vector and the details of amino acids sequence of ibHLH protein, inserted in the multiple cloning 
site of pIRES2-EGFP. bHLH basic helix-loop helix, HIF-1a hypoxia inducible factor-1a, Arnt aryl hydrocarbon receptor nuclear translocator, ODD 
oxygen-dependent degradation, NLS nuclear localization signal
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The induction of hypoxia with  CoCl2
Treating HEK293T with  CoCl2 significantly increased 
the expression of VEGF as the main downstream gene of 
HIF-1a, at both 150 µM (p < 0.01) and 200 µM (p < 0.001) 
concentrations after 48 h (Fig. 3a).  CoCl2 at concentration 
of 200  µM induced a 4.6-fold increase on the expres-
sion of the VEGF gene. Similarly, the cellular level of the 
HIF-1a protein was increased in time and dose-depend-
ent  manner by  CoCl2 (Fig.  3b). Therefore, treatment of 
the cells at 200 µM concentration for 48 h was considered 
as the optimal hypoxia condition for HEK293T cells.
The efficiency of transfection and the viability of HEK293T 
cell after transfection
The rate of transfection of HEK293T with control 
pIRES2-EGFP and ibHLH pIRES2-EGFP were 78% and 
87% respectively, 48 h post-transfection (Fig. 4) and the 
transfection assay had no significant effect on the viabil-
ity of HEK293T cells (Fig. 5).
The effect of ibHLH on the expression of different genes, 
involved in angiogenesis and EMT of tumor cells
As expected, gene expression of VEGF (Fig. 6c, p < 0.001), 
vimentin (Fig.  6e, p < 0.001), and β-catenin (Fig.  6f, 
p < 0.01) were significantly increased after treatment of 
untransfected HEK293T cells with 200  µM  CoCl2 for 
48 h.
Gene expression of VEGF, N-cadherin, vimentin and 
β-catenin was decreased in the cells transfected with 
either control or ibHLH vectors during hypoxia. How-
ever, this reduction was only statistically significant for 
the case of vimentin (p < 0.01).
Regarding the net effect of ibHLH, we observed that 
ibHLH had more inhibitory effects on gene expression 
of N-cadherin and β-catenin compared to the control 
Fig. 2 The effect of different concentration of  CoCl2 on the viability 
of HEK293T after 24 h and 48 h. Data represents the mean (± SD) of 
the percentage of viability from two independent experiments, each 
performed in triplicate. Statistically analysis was performed on the 
percentage of viability, using One-way ANOVA, Bonferroni. Error bars 
indicate ± SD. (*p < 0.05, **p < 0.01, ***p < 0.001, N/S: Not significant)
Fig. 3 Hypoxia induction on HEK293T with  CoCl2. a Fold change expression of VEGF mRNA after treating with different concentrations of  CoCl2 
for 24 h and 48 h. Data represents the mean (± SD) of fold changes from two independent experiments, each performed in triplicate. Statistically 
analysis was performed on Log2 Fold Change, using One-way ANOVA, Bonferroni. Error bars indicate ± SD. (*p < 0.05, **p < 0.01, ***p < 0.001, N/S not 
significant). b Western blot analysis of protein expression of HIF-1a after treating with different concentrations of  CoCl2 for 24 h and 48 h
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vector. However, it was not statistically significant. More-
over, there was no difference in hypoxia-depended 
expression of VEGF and vimentin between the cells 
transfected with ibHLH and control vector.
The effect of ibHLH on the protein expression 
of N‑cadherin and β‑catenin
Similarity to what occurred at the gene level, at the 
protein level, we observed that ibHLH reduced pro-
tein expression of N-cadherin more than the control 
vector (Fig.  7a). However, it was not statistically sig-
nificant (p > 0.05). Moreover, we could not find any dif-
ference between the control and the ibHLH vectors in 
reducing the protein level of β-catenin (Fig. 7b).
Discussion
HIF-1 is the most prominent transcriptional factor of 
hypoxia and has crucial involvement in different hall-
marks of cancer phenotypes, making it an attractive tar-
get for developing a novel therapeutic approach in the 
Fig. 4 Photograph of the EGFP-transfected HEK293T obtained with a fluorescence microscope and rate of transfection obtained with 
flow-cytometry, 48 h after transfection. a Un-transfected cells, b Transfected with control pIRES2-EGFP, and c Transfected with ibHLH pIRES2-EGFP
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field of personalized medicine. In this study, we devel-
oped a new specific HIF-1 inhibitor protein by target-
ing the bHLH domains of this transcriptional factor 
(ibHLH), in order to inhibit the DNA binding activity of 
HIF-1. We found that both the control and the ibHLH 
vectors decreased the hypoxia-depended gene expression 
of VEGF, N-cadherin, vimentin, and β-catenin as well 
as the protein level of β-catenin. However, there was no 
significant difference between the control vector and the 
ibHLH vectors in reducing the gene and their protein 
levels. It seems that the overexpression of ibHLH protein 
is not sufficient to significantly inhibit endogenous HIF-1 
Fig. 5 The effect of transfection on the viability of HEK293T, 48 h after transfection by Propidium Iodide staining. a Un-transfected HEK293T cells, 
and b Transfected with ibHLH pIRES2-EGFP
Fig. 6 The effect of ibHLH pIRES2-EGFP on the hypoxic-depended expression of ibHLH (a), HIF-1a (b), VEGF (c), N-cadherin (d), Vimentin (e), and 
β-catenin (f). Data represent the mean (± SD) of Fold Changes from two independent experiments, each performed in duplicate. Statistically 
analysis was performed on Log2 Fold Changes, using One-way ANOVA, Bonferroni. Error bars indicate ± SD. (*p < 0.05, **p < 0.01, ***p < 0.001, N/S 
not significant)
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transcriptional activity and more studies about the exact 
molecular structure of the domains that mediate critical 
functions of HIF-1 is necessary for developing a specific 
HIF-1 inhibitor.
Hypoxia as a prominent feature of solid tumors has 
been targeted in several studies. However, most of the 
HIF-1 inhibitors described so far in the literature are 
non-specific; thus, differentiation of their contribution to 
HIF-1 and other pathways is difficult. Therefore, develop-
ment of further specific inhibitors that could selectively 
inhibit HIF-1; needs to be studied.
The critical role of bHLH in DNA binding has been 
reported in several studies [20–22, 26]. HIF-1a-Arnt rec-
ognizes the HRE sequences of different genes through 
specific amino acids in bHLH domains. The basic region 
of bHLH contributes to HRE recognition and the helix-
loop-helix regions of theses domains form a helical 
bundle around the DNA and insert a major groove in 
a pseudo-symmetric fashion [22, 27]. Echinomycin, a 
natural cyclic peptide belonging to quinoxaline antibi-
otic family, has been introduced as a small inhibitor that 
interferes with the HIF-1–DNA interaction [19]. How-
ever, echinomycin is not the HIF specific inhibitor and 
confirmation of its cytotoxicity in several clinical trial 
phases has limited its clinical application [10].
More specifically, HIF-1a bHLH-PAS and Arnt bHLH-
PAS truncated proteins have been reported to mediate 
the DNA-binding activity of HIF-1 [19]; however, no 
further examination has been done on these truncated 
proteins yet. In order to explore the HIF-1–DNA bind-
ing inhibition of proteins with small size, we designed a 
truncated protein, containing only the bHLH domains of 
HIF-1a and Arnt (which we called it ibHLH) to compe-
tent with HIF-1 in binding to the HRE sequence. To test 
our hypothesis, we induced hypoxia in HEK293T cells 
and transfected the cells with the  PIRES2-EGFP vector 
expressing the ibHLH.
Fig. 7 The effect of ibHLH pIRES2-EGFP on the protein expression of N-cadherin (a), and β-catenin (b). Data represent the median (± IQR) of 
normalized protein expression with β-actin from one experiment, performed in triplicate. Statistically analysis was performed on protein expression, 
using Kruskal–Wallis, Dunn test, Benjamini–Hochberg. Error bars indicate ± IQR. (*p < 0.05, **p < 0.01, ***p < 0.001, N/S not significant)
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Firstly, hypoxia was successfully induced in HEK293T 
cells.  CoCl2 treatment significantly increased gene 
expression levels of VEGF, vimentin and β-catenin and 
the protein level of HIF-1a.  CoCl2 prevents HIF-1a 
hydroxylation by occupying an iron-binding site on the 
proline hydroxylases enzyme, thereby causing HIF-1a 
accumulation in normoxia condition [28]. The accumu-
lated HIF-1a moves to the nucleus, dimers with Arnt and 
activates the expression of downstream genes of HIF-1, 
and is involved in angiogenesis, epithelial to mesenchy-
mal transition (EMT), invasion, and metastasis [29–34].
Although  CoCl2 increased the expression of the HIF-
1a protein, HIF-1a mRNA was down regulated 48-h post 
treatment. Similar observations had been previously 
reported in breast cancer cell lines. Chu et  al. showed 
that  CoCl2 treatment increased the protein expression of 
HIF-1a in MCF-7 and MDA-MB-231 cell lines; however, 
mRNA expression decreased within the same periods of 
treatment, as we observed [35]. It seems that reduced 
levels of mRNA expression might be a negative feedback 
mechanism for inhibiting the HIF-1a accumulation fol-
lowing continuous exposure to  CoCl2.
Secondly, the hypoxic cells were transfected with con-
trol and ibHLH expressing vectors. The ibHLH vector 
was successfully transcripted (Fig.  7a) and translated in 
the transfected cells (Fig.  4). However, further analysis 
indicated that ibHLH failed to significantly inhibit the 
activation of HIF-1 downstream genes, suggesting that 
some other regions of HIF-1 protein might be responsi-
ble for this process.
VEGF is the main downstream gene of HIF-1a and its 
overexpression has been used to validate hypoxia induc-
tion in most studies [36, 37]. In this study, overexpression 
of ibHLH has no effect on the gene expression of VEGF, 
while another HIF-DNA interfering molecule, echinomy-
cin, has been reported to bind the HRE sequence in the 
VEGF promoter and directly inhibit the VEGF mRNA 
expression [19, 38]. Synthetic pyrrole-imidazole poly-
amide also targets the HRE sequence in the VEFG pro-
moters, and inhibit the VEGF mRNA and protein level 
in  vitro. However, their development as therapeutics 
remains to be further established [39]. Therefore, further 
investigation for developing a novel HIF-1 DNA binding 
inhibitor is still warranted.
Researches have demonstrated that low oxygen level 
is associated with the process of EMT through expres-
sion of HIF-1 protein [40]. HIF-1a increases the gene 
expression of snail and subsequently induces cell migra-
tion through increasing the mesenchymal markers such 
as N-cadherin and vimentin [41]. In contrast, β-catenin 
is directly regulated by HIF-1 through β-catenin-HRE 
interaction [42] or indirectly by expression of BCL9 in 
hypoxia [43]. Zhu et  al. has reported HIF-1α siRNA 
significantly suppresses the expression of N-cadherin, 
both at the gene and the protein level, suggesting a pos-
sible therapeutic strategy to prevent hypoxia-induced 
EMT [44]. Recently, sanguinarine has been found to 
inhibit the EMT via targeting translocation of HIF-1α 
from cytosol to the nucleus during hypoxia [45]. How-
ever, to the  best of our knowledge, the effect of DNA 
binding inhibitors such as echinomycin and polyamides 
on EMT markers have not been evaluated in the previous 
studies. In this study, we observed that overexpression of 
ibHLH mediated the hypoxia-dependent expression of 
β-catenin and N-cadherin. Although it was not statisti-
cally significant,  it  can be  speculated that the affinity of 
ibHLH to HRE sequence was not strong enough to sig-
nificantly inhibit the gene expression levels. Wu and his 
colleagues demonstrated the PAS domain of HIF-1a con-
tributes to DNA binding affinity [22]. They showed that 
the PAS domain binds DNA at distance six base pairs 
away from the hexameric core element and mutations in 
PAS domain can reduce the affinity of HIF-1 to the HRE 
sequence. However, ibHLH had no effect in inhibiting the 
transcription of VEGF under hypoxia condition, as it is 
the main downstream gene of HIF. It seems that the func-
tion of PAS on DNA binding is not restricted to the affin-
ity of DNA and may play a greater role in this process 
than previously suggested.
PAS domains were known as the main domains in 
dimerization of HIF-1a-Arnt. Targeting the PAS domain 
showed a promising result in inhibiting the dimerization 
of HIF-1a-Arnt and in further diminishing the HIF-1 
transcriptional activity [46–49]. However, there are lim-
ited studies available about the capability of PAS in DNA 
interaction. For an appropriate HIF-1-HRE interaction, 
HIF-1 should recognize the HRE sequence, be able to 
bind this sequence and the affinity of interaction should 
be high. Current literature about the role of HIF domains 
in mentioned steps is limited and further studies regard-
ing the specific role of PAS in DNA recognition, DNA 
binding and DNA affinity should be performed.
The research findings of this study were limited by lack 
of DNA-binding techniques such as quantitative Elec-
trophoretic Mobility Shift Assay. This technique assesses 
the protein-DNA interaction [50] and is useful to study 
the attachment of ibHLH to HRE sequence and provides 
more robust evidence on this topic. Further studies with 
more specific DNA-binding assays are needed to reach 
a more conclusive result about the interaction of ibHLH 
and HRE sequence.
Conclusion
In overall, despite of the critical role of bHLH in bind-
ing HIF-1 to HRE sequence of different genes, it seems 
that targeting this domain has failed to inhibit the 
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endogenous transcriptional activity of HIF-1. Probably 
the presence of the PAS domain might increase the effi-
ciency of this specific inhibitor. Further studies with 
more robust assays need to be performed to compare 
the effect of bHLH with bHLH-FAS in targeting the 
DNA-binding activity of HIF-1a pathway. Moreover, 
deciphering the molecular structure of HIF-1a domains 
and their critical functions in this pathway are impor-
tant for developing a novel specific inhibitor.
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